小児腫瘍学における化学療法による骨粗鬆症: 病理生理学と治療法
Jakub Pobideł1, Julia Piekarz2, Natalia Picheta1
1Student Academic Group, Department of Clinical Oncology and Chemotherapy, Medical University, Lublin, Poland.
Pediatric endocrinology, diabetes, and metabolism
|February 16, 2026
まとめ
青少年の骨粗鬆症は,がん治療による小児がんの生存者にとって懸念が高まっている. 早期の多学科的介入は,骨の損失を管理し,長期的な健康を改善するために不可欠です.
科学分野:
- 小児腫瘍学 小児腫瘍学
- 骨代謝についてです.
- 癌の生存率 がんの生存率
背景:
- 化学療法やグルココルチコイドなどの小児がん治療は,骨格の発達を妨げます.
- 積極的ながん治療は,炎症,酸化ストレス,ホルモン欠乏,薬物毒性による骨の喪失につながる可能性があります.
- ヒポゴナディズムや成長ホルモンの欠乏症などの内分泌症は,小児がん患者の骨質獲得をさらに損なう.
研究 の 目的:
- 癌の小児における治療による骨の喪失の多因子の病理生理学を見直す.
- 治療の毒性,ホルモンの不均衡,行動の変化を含む要因を概説する.
- 小児がんの生存者における二次性骨粗鬆症の診断上の課題と潜在的な介入について議論する.
主な方法:
- 小児腫瘍学における若年性骨粗鬆症に関する研究の文献レビュー.
- 細胞および分子経路を含む,骨の損失を誘発するメカニズムの分析.
- 遺伝的要因,診断の複雑さ,および現在の/新興の介入の検討.
主要な成果:
- 癌治療は,骨質芽細胞の機能を低下させ,メトトレキサートやグルココルチコイドのような薬剤を通じて骨質芽細胞形成を促進します.
- 内分泌病,栄養不足,身体的不活性,心理的疲労は骨の衰えを合併する.
- 遺伝的要因 (例えば,LRP5,ESR1変異) と診断の変動性は,管理を複雑にする.
結論:
- 小児がんの生存者における二次性骨粗鬆症は,腫瘍学的,代謝的,行動的,遺伝的要因の複雑な相互作用の結果である.
- 早期発見と継続的なモニタリングは,骨密度の管理に不可欠です.
- 身体活動,栄養,内分泌の評価,およびビスホスフォネートを含む多学科戦略は,骨の完全性を保ち,生活の質を向上させるために不可欠です.
関連する概念動画
02:49Cancer Therapies
10.2K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.2K
02:50Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
256
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
256
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
718
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
718
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
284
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
284
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
335
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
335